Clinical Trials

Institution: Multiple

Type: Multi-Center Trial

Purpose: To evaluate the efficacy of two doses of GLPG1690 in addition to local standard of care compared to placebo in subjects with idiopathic pulmonary fibrosis (IPF) as evaluated by the rate of decline of forced vital capacity (FVC) over a period of 52 weeks.

Dates: November 5, 2018 - December 15, 2021

Disease: Pulmonary Fibrosis



Ann Fieuw
[email protected]

Page last updated: April 10, 2020

Yoga Power
Orlando, FL | Dec 02, 2019
Better Breathers Club | Atrium Health: Cabarrus
Concord, NC | Mar 26, 2020